Xeljanz
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Xeljanz (tofacitinib; Pfizer/Takeda) is an oral small molecule inhibitor of Janus kinases (JAKs). The drug prevents the binding of cytokines to JAKs, which in turn blocks the JAK/STAT signaling pathway required to activate the gene expression in various immune cells. Xeljanz also impairs the differentiation of critical immune cells such as T helper cells.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Xeljanz : Psoriasis
13 Xeljanz : Psoriatic arthritis
20 Xeljanz : Inflammatory bowel disease
36 Xeljanz : Rheumatoid arthritis
LIST OF FIGURES
16 Figure 1: Xeljanz for psoriatic arthritis – SWOT analysis
16 Figure 2: Datamonitor Healthcare’s drug assessment summary of Xeljanz in psoriatic arthritis
17 Figure 3: Datamonitor Healthcare’s drug assessment summary of Xeljanz in psoriatic arthritis
25 Figure 4: Results from Phase II trial of Xeljanz in ulcerative colitis
28 Figure 5: Results from Phase II trial of Xeljanz in Crohn’s disease
28 Figure 6: Xeljanz for Crohn’s disease and ulcerative colitis – SWOT analysis
29 Figure 7: Datamonitor Healthcare drug assessment of Xeljanz in Crohn’s disease
30 Figure 8: Datamonitor Healthcare drug assessment of Xeljanz in Crohn’s disease
31 Figure 9: Datamonitor Healthcare drug assessment of Xeljanz in ulcerative colitis
31 Figure 10: Datamonitor Healthcare drug assessment of Xeljanz in ulcerative colitis
44 Figure 11: Xeljanz’s SWOT analysis in rheumatoid arthritis
45 Figure 12: Datamonitor Healthcare’s drug assessment summary of Xeljanz in rheumatoid
arthritis
46 Figure 13: Datamonitor Healthcare’s drug assessment summary of Xeljanz in rheumatoid
arthritis
LIST OF TABLES
4 Table 1: Xeljanz drug profile
7 Table 2: Xeljanz pivotal late-phase trials in psoriasis
13 Table 3: Xeljanz drug profile
15 Table 4: Xeljanz Phase III data in psoriatic arthritis
20 Table 5: Xeljanz drug profile
23 Table 6: Ongoing pivotal trials of Xeljanz in ulcerative colitis
27 Table 7: Ongoing clinical trials of Xeljanz in Crohn’s disease
36 Table 8: Xeljanz’s drug profile in rheumatoid arthritis
37 Table 9: Overview of pivotal trial data for Xeljanz in rheumatoid arthritis
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Siliq 
Sign up to the